Article: Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial

File Download
  • No File Attached
Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleEffect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial
AuthorsTunggal, P2
Ng, FH2
Lam, KF1
Chan, FKL3
Lau, YK2
Issue Date2011
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ahj
CitationAmerican Heart Journal, 2011, v. 162 n. 5, p. 870-874 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.ahj.2011.08.007
AbstractBackground: Previous studies showed that esomeprazole does not interfere significantly with the platelet inhibitory effect of clopidogrel. It is unknown whether famotidine, a histamine 2 receptor antagonist, interacts with clopidogrel. This double-blind, randomized study aimed to compare the influence of esomeprazole and famotidine on the platelet inhibitory effect of clopidogrel. Methods: Patients with acute coronary syndrome or elective percutaneous coronary interventions treated with aspirin and clopidogrel cotherapy were randomized to receive esomeprazole 20 mg daily or famotidine 40 mg daily. Platelet reactivity units (PRUs) were measured at baseline and on day 28. The primary analysis involved the PRU values on day 28. Results: There were 44 patients in the esomeprazole group and 44 in the famotidine group. The baseline PRUs of the 2 groups were comparable (esomeprazole vs famotidine, 229.1 ± 85.6 vs 220.4 ± 83.0, P =.63). The PRUs on day 28 were 242.6 ± 89.7 and 237.5 ± 79.2 in the groups receiving esomeprazole and famotidine, respectively (mean difference 5.1, 95% CI -30.8 to 41.0, P =.78). Conclusions: The platelet inhibitory effect of clopidogrel was not significantly different between patients receiving esomeprazole and those receiving famotidine. Neither esomeprazole nor famotidine reduced the platelet inhibitory effect of clopidogrel. © 2011 Mosby, Inc. All rights reserved.
ISSN0002-8703
2011 Impact Factor: 4.651
2011 SCImago Journal Rankings: 0.541
DOIhttp://dx.doi.org/10.1016/j.ahj.2011.08.007
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorTunggal, P
dc.contributor.authorNg, FH
dc.contributor.authorLam, KF
dc.contributor.authorChan, FKL
dc.contributor.authorLau, YK
dc.date.accessioned2012-08-16T05:59:13Z
dc.date.available2012-08-16T05:59:13Z
dc.date.issued2011
dc.description.abstractBackground: Previous studies showed that esomeprazole does not interfere significantly with the platelet inhibitory effect of clopidogrel. It is unknown whether famotidine, a histamine 2 receptor antagonist, interacts with clopidogrel. This double-blind, randomized study aimed to compare the influence of esomeprazole and famotidine on the platelet inhibitory effect of clopidogrel. Methods: Patients with acute coronary syndrome or elective percutaneous coronary interventions treated with aspirin and clopidogrel cotherapy were randomized to receive esomeprazole 20 mg daily or famotidine 40 mg daily. Platelet reactivity units (PRUs) were measured at baseline and on day 28. The primary analysis involved the PRU values on day 28. Results: There were 44 patients in the esomeprazole group and 44 in the famotidine group. The baseline PRUs of the 2 groups were comparable (esomeprazole vs famotidine, 229.1 ± 85.6 vs 220.4 ± 83.0, P =.63). The PRUs on day 28 were 242.6 ± 89.7 and 237.5 ± 79.2 in the groups receiving esomeprazole and famotidine, respectively (mean difference 5.1, 95% CI -30.8 to 41.0, P =.78). Conclusions: The platelet inhibitory effect of clopidogrel was not significantly different between patients receiving esomeprazole and those receiving famotidine. Neither esomeprazole nor famotidine reduced the platelet inhibitory effect of clopidogrel. © 2011 Mosby, Inc. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationAmerican Heart Journal, 2011, v. 162 n. 5, p. 870-874 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.ahj.2011.08.007
dc.identifier.doihttp://dx.doi.org/10.1016/j.ahj.2011.08.007
dc.identifier.epage874
dc.identifier.hkuros205610
dc.identifier.issn0002-8703
2011 Impact Factor: 4.651
2011 SCImago Journal Rankings: 0.541
dc.identifier.issue5
dc.identifier.pmid22093203
dc.identifier.scopuseid_2-s2.0-81255214744
dc.identifier.spage870
dc.identifier.urihttp://hdl.handle.net/10722/159913
dc.identifier.volume162
dc.languageeng
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ahj
dc.publisher.placeUnited States
dc.relation.ispartofAmerican Heart Journal
dc.relation.referencesReferences in Scopus
dc.subject.meshAcute Coronary Syndrome - blood - drug therapy
dc.subject.meshAnti-Ulcer Agents - administration and dosage
dc.subject.meshFamotidine - administration and dosage
dc.subject.meshOmeprazole - administration and dosage
dc.subject.meshPlatelet Aggregation Inhibitors - administration and dosage
dc.titleEffect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Ruttonjee Hospital Hong Kong
  3. Chinese University of Hong Kong